Detection of Molecular Signatures of Homologous Recombination Deficiency in Bladder Cancer.
Judit BörcsökMiklos DiossyZsófia M SztupinszkiAurel ProszViktoria TiszaSándor SpisákOrsolya RuszDag Rune StormoenHelle PappotIstvan CsabaiSøren BrunakKent W MouwZoltan SzallasiPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
A subset of bladder tumors have genomic features suggestive of HRD and therefore may be more likely to benefit from therapies such as platinum agents and PARP inhibitors that target tumor HRD.